Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research. Cryotherapy as primary treatment for localized prostate cancer (update) Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). Technote TN 54. 2005 Authors' objectives This Technote has been prepared in response to a request from Capital Health for an update on the status of cryotherapy for the primary treatment of localized prostate cancer.
Authors' conclusions Cryotherapy, when used as primary treatment for localized prostate cancer, is a promising technology based on calculation of 5- to 7-year probability-of-survival rates, reduction of prostate-specific antigen (PSA) values, and biopsy findings. Moreover, the technology continues to evolve in terms of instrumentation and the biology of cryotherapy. The place of cryotherapy among traditional therapies (radical prostatectomy, radiation therapy, and watchful waiting) has yet to be determined by comparative studies. Also, the specific population that would be most appropriate for this therapy has yet to be established.
INAHTA brief and checklist Indexing Status Subject indexing assigned by CRD MeSH Cryotherapy; Prostate-Specific Antigen; Prostatic Neoplasms /therapy Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence 1200, 10405 Jasper Avenue, Edmonton, Alberta, Canada, T5J 3N4. Tel: +1 780 448 4881; Fax: +1 780 448 0018; Email: djuzwishin@ihe.ca AccessionNumber 32006000243 Date bibliographic record published 03/04/2006 Date abstract record published 03/04/2006 |